 Leland Shapiro
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha 1-Antitrypsin | 9 | 2015 | 104 | 1.290 |
Why?
| | alpha 1-Antitrypsin Deficiency | 3 | 2013 | 61 | 0.610 |
Why?
| | Shock, Septic | 1 | 2021 | 227 | 0.580 |
Why?
| | HIV Infections | 6 | 2024 | 3193 | 0.450 |
Why?
| | Meningitis, Cryptococcal | 3 | 2024 | 34 | 0.450 |
Why?
| | Sepsis | 1 | 2021 | 664 | 0.430 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1217 | 0.330 |
Why?
| | Cryptococcosis | 2 | 2023 | 31 | 0.330 |
Why?
| | Interleukin-1beta | 3 | 2014 | 389 | 0.320 |
Why?
| | Cryptococcus | 2 | 2024 | 16 | 0.320 |
Why?
| | HIV-1 | 3 | 2015 | 908 | 0.290 |
Why?
| | Nitric Oxide | 2 | 2012 | 892 | 0.270 |
Why?
| | Interleukin-8 | 1 | 2009 | 269 | 0.270 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.260 |
Why?
| | Interferon-gamma | 3 | 2007 | 784 | 0.260 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 339 | 0.250 |
Why?
| | Mycobacteriaceae | 1 | 2007 | 34 | 0.240 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 91 | 0.240 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2007 | 127 | 0.230 |
Why?
| | Interleukin-18 | 1 | 2007 | 234 | 0.230 |
Why?
| | Interleukin-10 | 1 | 2007 | 309 | 0.220 |
Why?
| | Cytomegalovirus | 1 | 2026 | 168 | 0.220 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 206 | 0.210 |
Why?
| | DNA, Viral | 1 | 2026 | 356 | 0.200 |
Why?
| | Cryptococcus neoformans | 1 | 2024 | 21 | 0.200 |
Why?
| | Macrophages | 2 | 2012 | 1507 | 0.200 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 130 | 0.190 |
Why?
| | Anti-HIV Agents | 2 | 2007 | 912 | 0.180 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 171 | 0.160 |
Why?
| | Cytokines | 4 | 2021 | 2067 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 39 | 0.150 |
Why?
| | Medical Errors | 1 | 2020 | 119 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1140 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 356 | 0.120 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2008 | 70 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 740 | 0.120 |
Why?
| | Adult | 13 | 2026 | 40777 | 0.120 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 12 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1061 | 0.110 |
Why?
| | Middle Aged | 11 | 2026 | 36215 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1137 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
| | Humans | 22 | 2026 | 145474 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
| | Virus Activation | 1 | 2015 | 94 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.100 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 12 | 0.100 |
Why?
| | Virus Replication | 2 | 2021 | 521 | 0.100 |
Why?
| | Mycoses | 1 | 2014 | 88 | 0.100 |
Why?
| | Propensity Score | 2 | 2026 | 377 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2014 | 147 | 0.090 |
Why?
| | RNA, Viral | 2 | 2021 | 692 | 0.090 |
Why?
| | NF-kappa B | 2 | 2015 | 666 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 162 | 0.090 |
Why?
| | Male | 14 | 2026 | 72842 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2378 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Dendritic Cells, Follicular | 1 | 2011 | 5 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2012 | 288 | 0.080 |
Why?
| | Female | 14 | 2026 | 78844 | 0.080 |
Why?
| | Phosphorylation | 2 | 2012 | 1707 | 0.080 |
Why?
| | Monocytes | 1 | 2014 | 539 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2012 | 762 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 345 | 0.080 |
Why?
| | Emphysema | 1 | 2011 | 100 | 0.080 |
Why?
| | I-kappa B Proteins | 1 | 2011 | 75 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 499 | 0.080 |
Why?
| | Epoprostenol | 1 | 2010 | 132 | 0.070 |
Why?
| | Blood Cells | 1 | 2009 | 38 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2588 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 848 | 0.070 |
Why?
| | Staphylococcus epidermidis | 1 | 2009 | 79 | 0.070 |
Why?
| | Risk Factors | 5 | 2024 | 10885 | 0.070 |
Why?
| | Physical Endurance | 1 | 2010 | 279 | 0.070 |
Why?
| | Islets of Langerhans | 1 | 2014 | 846 | 0.060 |
Why?
| | Aged | 7 | 2026 | 26153 | 0.060 |
Why?
| | Placebos | 1 | 2007 | 193 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2823 | 0.060 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2007 | 48 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 385 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2010 | 2062 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 519 | 0.060 |
Why?
| | Transplantation Tolerance | 1 | 2005 | 39 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3922 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4148 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2507 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2018 | 3623 | 0.050 |
Why?
| | Phenotype | 2 | 2012 | 3155 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2440 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2024 | 531 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 222 | 0.040 |
Why?
| | Mice | 3 | 2012 | 18329 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 328 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5904 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.030 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 378 | 0.030 |
Why?
| | Prognosis | 1 | 2026 | 4316 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Animals | 4 | 2012 | 38030 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1300 | 0.030 |
Why?
| | Hospitals, University | 1 | 2016 | 176 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 6013 | 0.030 |
Why?
| | Inflammation | 1 | 2007 | 2878 | 0.030 |
Why?
| | Clathrin | 1 | 2015 | 26 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 7123 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2016 | 202 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 131 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 213 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 8057 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 554 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 484 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2018 | 17291 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 168 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2014 | 30 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1547 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 140 | 0.030 |
Why?
| | Hearing Loss | 1 | 2018 | 249 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 14218 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2014 | 151 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 193 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 29 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 100 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2134 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 57 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 487 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2121 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 48 | 0.020 |
Why?
| | PPAR alpha | 1 | 2011 | 55 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 618 | 0.020 |
Why?
| | Polyubiquitin | 1 | 2011 | 8 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2011 | 50 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 131 | 0.020 |
Why?
| | Lung Diseases | 1 | 2018 | 780 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 23 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 344 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 242 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2865 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 161 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 86 | 0.020 |
Why?
| | PPAR gamma | 1 | 2011 | 178 | 0.020 |
Why?
| | Ubiquitination | 1 | 2011 | 118 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 148 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 247 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 221 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1273 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 475 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 385 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 552 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 428 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 22529 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 645 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 599 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 847 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 418 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 11772 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4553 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 5983 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2008 | 503 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 2005 | 31 | 0.010 |
Why?
| | Granulocytes | 1 | 2005 | 81 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 2005 | 26 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 182 | 0.010 |
Why?
| | Walking | 1 | 2010 | 542 | 0.010 |
Why?
| | Cell Movement | 1 | 2008 | 959 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2445 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 364 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8333 | 0.010 |
Why?
| | Child | 2 | 2014 | 22707 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5584 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3542 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2005 | 480 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2930 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2005 | 961 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4560 | 0.010 |
Why?
| | Heart Failure | 1 | 2014 | 2326 | 0.010 |
Why?
| | United States | 1 | 2018 | 16098 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1097 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2597 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4295 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 2198 | 0.010 |
Why?
|
|
Shapiro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|